Typhoid Fever Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Typhoid Fever Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulation, which provide immunity and protects an individual against typhoid fever
Currently there are three typhoid vaccines recommended World Health organization (WHO) for use which include:
Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age;
Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above; and
Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age.
Market Dynamics
High prevalence of typhoid fever in region such as Asia Pacific and Africa is expected to drastically rise demand for its vaccines and support global typhoid fever vaccines market growth over the forecast period.
For instance, according to the data published by World Health Organization (WHO) in September 2018, globally between 11 and 21 million cases of typhoid were found, which caused around 128 000 to 161 000 typhoid-related deaths occur annually.
According to the data published by National Center for Biotechnology Information (NCBI) in 2018, incidence of typhoid fever in Africa was estimated to be 10–100 cases per 100,000
Increasing initiatives by government and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to support typhoid fever vaccines market growth during forecast period.
For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, CDC and Zimbabwe’s Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe’s capital with new typhoid conjugate vaccine (TCV).
Key features of the study:
This report provides in-depth analysis of Typhoid fever vaccines market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global Typhoid fever vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global Typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Typhoid fever vaccines market
Detailed Segmentation:
Global Typhoid Fever Vaccines Market, By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
Global Typhoid Fever Vaccines Market, By Route of Administration:
Oral
Parenteral
Global Typhoid Fever Vaccines Market, By Geography:
North America
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
U.S.
Canada
Europe
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
GCC
Israel
Rest of Middle East
Africa
By Vaccine Type :
Live Attenuated Vaccine
Capsular Polysaccharide Vaccines
Conjugate Vaccine
Others
By Route of Administration:
Oral
Parenteral
By Country:
Central Africa
South Africa
North Africa
Company Profiles
GlaxoSmithKline Plc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Sanofi SA
Bharat Biotech
Bio-Med Pvt. Ltd.
PT Bio Farma
PaxVax, Inc.
Shanghai Institute of Biological Products Co., Ltd.
Prokarium
“*” marked represents similar segmentation in other categories in the respective section.